Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | XBP1 | P17861 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 2/20 | 0.38 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.36 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL785634 | 1.00 | DRD3 (0.39) | DRD3ALDH1A1XBP1HTTACHE | |
| SCHEMBL803555 | 0.88 | ACHE (0.38) | DRD3ALDH1A1XBP1HTTACHE | |
| SCHEMBL803776 | 0.86 | DRD3 (0.40) | DRD3ALDH1A1ACHETRPM8SRD5A2 | |
| SCHEMBL784605 | 0.86 | DRD3 (0.40) | DRD3ALDH1A1ACHETRPM8SRD5A2 | |
| SCHEMBL803268 | 0.80 | ALDH1A1 (0.42) | DRD3ALDH1A1XBP1HTTACHE | |
| SCHEMBL785380 | 0.80 | ALDH1A1 (0.42) | DRD3ALDH1A1XBP1HTTACHE | |
| SCHEMBL13131171 | 0.78 | ACHE (0.57) | DRD3ALDH1A1ACHETRPM8KDM1A | |
| SCHEMBL784750 | 0.78 | ALDH1A1 (0.40) | DRD3ALDH1A1XBP1HTTACHE | |
| SCHEMBL784751 | 0.78 | ALDH1A1 (0.40) | DRD3ALDH1A1XBP1HTTACHE | |
| SCHEMBL785252 | 0.78 | DRD3 (0.40) | DRD3ALDH1A1ACHETRPM8SRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| WO-2012038081-A1 | SUBSTITUTED BENZAMIDE COMPOUNDS | Grünenthal GmbH (DE) | 2012-03-29 | — | — | WO | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071461-A1 | Substituted Benzamide Compounds | BDKRB1, BDKRB2, HRH2 | DRD3 85/4885ALDH1A1 1267/4885XBP1 3609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.